SU85755A1 - A method of manufacturing a vaccine against infectious goat pleuropneumonia - Google Patents

Description

Usually, aluminum hydroxide-aluminum vaccines were prepared by virulent material and were taken against the plague of chickens, sheep, shch, and others, but they were not sufficiently effective against infectious pleuropneumus mosquitoes.

In the described method, for the manufacture of a hydroxide-aluminum formol vaccine, pulmonary tissue is taken as the initial virus-containing material, which is characterized by characteristic signs. thoracic / and pleural lymph nodes from goats, patients with an acute form of infectious pleuropneumonia with prominent clinically apparent symptoms on average 5-8 days of illness. The killed goats are skinned, the pin is removed, the small organs are separated, the head and back of the body are separated in the region of the vertebrae, and the chest part of the body is transferred to a sterile room. The lung tissue and lymphatic glands are opened and removed through the diaphragm or through the chest cavity, but the inflammatory eculate is extracted from the chest cavity. Opening and removal of organs produced by the manufacturer with strict asepsis.

Tissue with lesions characteristic of the acute form of the disease, namely, acute hypere, lung tissue and a stage of red and gray genation, is considered suitable for the manufacture of a vaccine. In most cases there is an accumulation of exudate and coagulated fibrin in the interpleural space. The resulting lung tissue n lymph glands are subjected to grinding in. M cutting. Grinding is carried out by successive use of cutting gratings with different aperture diameters in m (reducing to I mm).

Exudate from the interstitial space is obtained by inserting a fluid cannula or needle through the diaphragm, connecting it with a rubber hose and vessel.

For the manufacture of the vaccine take inflammatory exudate of the chest cavity, virulent crushed material, hydrokali aluminum

85755

and a buffer solution, which is mixed in the following proportions: 5 wt. adyumin hydroxide (6%); 4th day including phosphate buffer solution; weight. including viral suspension with subsequentin1, it is 38-40% in total 0.1% to the mixture by formalinactivation by formalin.

1 90 weight. including a steroid mixture of oxy-aluminum hydrate and a buffer solution was added 10 days. Part 1 of the liquid suspension, but of which it is produced by thoroughly stirring up the liquid (ngutlured) of the liquid for 30 MIH-.

After 24 hours holding the mixture to a cold place is formalinized at the rate of 0.1% formalin content; 38–40% formaldehyde is used for the amount of the mixture.

Having completed the formalization, the bottle of vaknina is closed and immediately the nronzBOD t is agitated for 5--6 minutes. and placed in a thermostat or room for inactivation for 48 hours. at temneru 1e 15-20 °.

After 48-hour Put the bottle in a bottle in a dark and cool place, preferably with a temperature of 5-10 °.

After packaging, the vaccine is subjected to bacteriological and biological control.

Bacteriological control is carried out by sowing on nutrient media. Crops are kept in a thermostat at a temperature of 37-38 ° for at least 10 days. In case of growth, the type and pathogenicity of microorganisms are established. The presence of non-pathogenic microflora in separate vaccine series cannot prevent its release for practical use.

Biological safety test is carried out:

on two rabbits in a dose of 2 slg

at sea dose1

ia two white iMbiinax at a dose of 0.2 ,,

The vaccine is administered subcutaneously to rabbits and guinea pigs in the abdominal area, while white mice are injected into the area.

The safety of the vaccine is also controlled on goats with a dose of 10 cm.

Vaccine activity tests are performed on goats. For this purpose, four goats, ages 1.5-3 years old, are injected with a dose of 5 cm in the field. Repeated vaccination was carried out after 7 days at the same doses. At the site of the vaccine, minor subcutaneous consolidations are usually formed due to the slow resolution of the oxy-aluminum oxide hydrate.

The challenge of infection with the people of the vaccinated goats is produced 13-15 days after the second vaccine vaccine. The virus in the form of a freshly exudate of a non-ple or 1 and a suspended tissue suspension is injected with four vaccinated and three control goats intratracheally at a dose of 1-2 cm. For the control of infection, no more than 3-day storage of the virus is allowed, at a temperature of 4-6 ° C.

A vaccine is considered active if, within 20 days of the observation period after the control infection, all four vaccinated I1 goats are not sick of, and three controllers must have an infectious pleuropneumonia clinic with detailed information on it.

If there are about four vaccinated goats, about ana becomes sick, but recovers, and all controls gobble up, the vaccine is also active.

The vaccine is also considered to be an act of panic disease under the condition of the disease of all three control, but the death of them two goats and one left in the ia-i.

The vaccine is used prophylactically twice by subcutaneous administration in doses of 3-5 cm, depending on the age of the goats.

Subject invention

Claims (2)

1. A method of manufacturing a vaccine against infectious goats pleuroinemonin, characterized in that lung tissue having characteristic lesions, lymph nodes of the chest cavity and pleural exudate from goats, patients with an acute form of infectious pleuropneumonia, is taken as the original virus-containing material. 2. Acceptance of the method according to claim 1, characterized in that, after grinding and filtering, the coil material is shifted from 5 wt. including 6% aluminum hydroxide, 4 wt. including a solution of phosphate buffer and 1 wt. including virulent material followed by inactivation of the virus with formalin, added in an amount of 0.1% to the entire mixture. - 3 -LE 85755